Percheron reports $4.79 million loss in FY2026 as HMBD-002 phase II trial preparation progresses

Losses Narrow as Percheron Advances HMBD-002 Clinical Development

Percheron Therapeutics Limited (ASX:PER) reported a significantly reduced loss of $4.79 million for the year ended 30 June 2026, down 68% from $14.92 million in FY2025. The improvement reflects the company's full expensing of research and development costs, including manufacturing clinical trial materials, and a lower share-based payments charge. Despite the narrower loss, cash reserves declined to $4.05 million from $10.17 million the prior year, underscoring ongoing funding needs as the company pushes its lead asset forward.

HMBD-002 Progress and Phase II Trial Plans

The oncology drug HMBD-002, licensed exclusively from Singapore-based Hummingbird Bioscience in June 2025, remains the centerpiece of Percheron's pipeline. The monoclonal antibody targets the VISTA immune checkpoint and completed a phase I trial in the US, demonstrating a strong safety profile both as monotherapy and combined with Keytruda (pembrolizumab). Notably, no maximum tolerated dose was reached due to scarce dose-limiting toxicities, a positive signal in early clinical development.

The company has manufactured a new batch of clinical trial material and is preparing for an international, adaptive multi-arm phase II trial targeting multiple tumour types. This trial, expected to start in the second half of calendar 2026, aims to generate efficacy data efficiently while exploring which cancers respond best to HMBD-002. The World Health Organization has provisionally named the drug 'minperstobart', marking its progression towards mid-clinical stage status.

Leadership Transition and Capital Management

Percheron announced the appointment of Dr Michael Baker as CEO effective 5 October 2026, succeeding Dr James Garner who will remain on the board as a non-executive director. Baker brings extensive biotech leadership experience, with remuneration structured to align with shareholder interests through a mix of reduced cash salary and performance-linked equity. Garner’s departure follows a tenure marked by navigating the company through licensing and early clinical milestones.

During FY2026, Percheron raised approximately $2.2 million via an entitlement offer and shortfall placements, bolstering its financial position to support ongoing clinical activities. The company continues to leverage the Australian Government’s R&D Tax Incentive, recognising $696,345 in rebates for the year.

Financial Position and Risks

While the loss narrowed, the company’s cash burn remains significant, with operating cash outflows of nearly $5 million in FY2026. The auditor highlighted a material uncertainty regarding Percheron’s ability to continue as a going concern without additional capital or partnering deals. The company’s risk profile includes typical biotech challenges: clinical development uncertainties, regulatory hurdles, competition, and the need for sustained funding.

Percheron’s strategy to mitigate these risks involves disciplined cost management, advancing HMBD-002’s clinical program, and exploring grant funding opportunities. The company’s intangible assets now include the HMBD-002 license valued at nearly $2.9 million after amortisation.

What Comes Next for Percheron?

The key near-term catalyst is the commencement of the phase II trial for HMBD-002, which will be critical to validating the drug’s efficacy and attracting potential partners or investors. Meanwhile, the market’s muted response to Percheron’s progress, despite promising safety data, reflects broader headwinds in ASX-listed biotech valuations. The incoming CEO’s ability to navigate clinical, regulatory, and capital market challenges will be pivotal in shaping Percheron’s trajectory.